#1 Clinical Trials Search in Europe

Study on Stopping Tocilizumab for Patients with Giant Cell Arteritis

3 1 1 1

What is this study about?

This clinical trial is focused on studying Giant Cell Arteritis, a condition that causes inflammation of the blood vessels, often in the head. The study will explore the effects of stopping treatment with tocilizumab, a medication used to manage this condition. Tocilizumab is administered as a solution for injection, either in a pre-filled pen or syringe, and is known by other names such as RoActemra and RO4877533.

The purpose of the study is to compare two different approaches to discontinuing tocilizumab: stopping it immediately or gradually over 24 weeks. Participants will be monitored for 26 weeks to see how well they do without the medication, focusing on whether they remain free from relapses, which are returns of disease symptoms. The study will also look at the overall health and quality of life of participants during this period.

Participants will receive either the immediate or gradual discontinuation strategy and will be followed up with regular check-ins to assess their health status. The study aims to provide insights into the best way to stop tocilizumab treatment while minimizing the risk of relapse and maintaining the well-being of individuals with Giant Cell Arteritis.

1 joining the study

Upon joining the study, you will be randomly assigned to one of two groups. One group will stop taking the medication tocilizumab immediately, while the other group will gradually reduce the dosage over 24 weeks.

2 medication administration

If you are in the gradual discontinuation group, you will continue to receive tocilizumab as a subcutaneous injection. The dosage is 162 mg, administered once a week. This will continue for up to 24 weeks, depending on your group assignment.

3 follow-up visits

You will have regular follow-up visits to monitor your health and the effectiveness of the treatment. These visits will occur at weeks 0, 12, 26, 52, and 78. During these visits, various assessments will be conducted, including quality of life evaluations and fatigue scoring.

4 monitoring and assessments

Throughout the study, your health will be closely monitored. This includes checking for any signs of relapse or side effects. Blood tests and imaging may be performed to assess your condition and the impact of the treatment.

5 end of study

The study will conclude after 78 weeks. At this point, a final assessment will be conducted to evaluate your health status and the overall outcomes of the treatment strategy you followed.

Who Can Join the Study?

  • Provide written consent to participate in the study.
  • Have stopped treatment with corticoids (a type of steroid medication) at least 12 weeks before joining the study. However, taking hydrocortisone (up to 20 mg per day) is allowed if the dose remains stable during the study.
  • Have a recent blood test (within 6 weeks) showing good tolerance to tocilizumab, a medication used in the study. The test should show:
    • AST and ALT (liver enzymes) less than 1.5 times the upper limit of normal.
    • Hemoglobin (a protein in red blood cells) greater than 8 g/dL.
    • Platelets (cells that help with blood clotting) greater than 100 G/L.
    • Neutrophils (a type of white blood cell) greater than 1 G/L.
    • Lymphocytes (another type of white blood cell) greater than 0.5 G/L.
  • Have a diagnosis of Giant Cell Arteritis (GCA), confirmed by:
    • Being at least 50 years old at the time of diagnosis.
    • Having a history of high ESR (a blood test that measures inflammation) of 50 mm/h or more, or high CRP (another inflammation marker) of 20 mg/L or more. This criterion is optional if a temporal artery biopsy is positive.
    • Having at least one clear sign of GCA, such as a recent headache, scalp tenderness, jaw pain when chewing, abnormal temporal artery, or vision problems due to lack of blood flow.
    • Having clinical signs of polymyalgia rheumatica (a condition causing muscle pain and stiffness).
    • Having evidence of GCA during follow-up, such as:
      • A temporal artery biopsy showing specific signs of GCA.
      • Evidence of inflammation in the temporal arteries using an echo-Doppler test.
      • Evidence of inflammation in large blood vessels using imaging tests like angio-CT, angio-MRI, or PET scan.
  • Have GCA in remission (no symptoms and CRP of 10 mg/L or less) for at least 12 weeks before joining the study.
  • Have been treated with tocilizumab (TCZ) or a similar medication, either through an IV (intravenous) or SC (subcutaneous) method, for 12 to 36 months before joining the study.
  • Have not stopped TCZ treatment for more than 12 weeks in the 12 months before joining the study.
  • Have been receiving subcutaneous TCZ (162 mg per week) or a similar medication for at least 12 consecutive weeks before joining the study.

Who Cannot Join the Study?

  • Patients with any other serious health condition that might interfere with the study.
  • Patients who are pregnant or breastfeeding.
  • Patients who have had a recent infection that required treatment with antibiotics.
  • Patients who have received any other investigational drug within the last 30 days.
  • Patients with a history of severe allergic reactions to any medication.
  • Patients with a history of cancer, except for certain types of skin cancer that have been treated.
  • Patients with uncontrolled high blood pressure.
  • Patients with severe liver or kidney disease.
  • Patients who have been vaccinated with a live vaccine within the last 4 weeks.
  • Patients who have a history of alcohol or drug abuse.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Centre Hospitalier Universitaire De Bordeaux Bordeaux France
University Hospital Of Clermont-Ferrand Clermont Ferrand France
Centre Hospitalier Regional Et Universitaire De Brest Brest France
Centre Hospitalier De Beziers Beziers France
CHU Grenoble Alpes La Tronche France

Other Sites

Site Name City Country Status
Centre Hospitalier D Avignon Avignon France
Hopitaux Universitaires Pitie Salpetriere Paris France
Centre Hospitalier Le Mans Le Mans France
Assistance Publique Hopitaux De Paris Paris France
Centre Hospitalier Universitaire De Nice Nice France
Centre Hospitalier De Dax Dax France
Union Mut Gestion Groupe Hosp Mutualiste De Grenoble Grenoble France
Centre Hospitalier Groupe Hospitalier De La Rochelle Re Aunis La Rochelle France
Centre Hospitalier De Perpignan Perpignan France
Hopital D’Instruction Des Armees Percy Clamart France
Hopitaux Prives De Metz Vantoux France
Centre Hospitalier De Valenciennes Valenciennes France
Centre Hospitalier Universitaire De Toulouse Toulouse France
Centre Hospitalier Saint Joseph Saint Luc Lyon France
Centre Hospitalier Universitaire De Nantes Nantes France
Hopital Saint Joseph Marseille France
Hospital Foch Suresnes France
Centre Hospitalier Universitaire De Poitiers Poitiers France
Centre Hospitalier Lyon Sud Pierre Benite France
Centre Hospitalier Universitaire De Caen Normandie Caen France
Hopital Purpan Toulouse France
Centre Hospitalier Tarbes-Lourdes Tarbes France
Cdpcth Huzygukcplg dt Mvxpj Macon France
Ckklerip Scrhi Evsiloq Toulouse France
Ccm ddnuduwarqijcm Epagny Metz Tessy France
Ckupbf Hfaphrwauuj Ey Uyrvivjbuxwpv Da Lluvqfx Limoges France
Ayguoudwhy Pzapecbi Hcvhqvlq Dw Pfpgc Paris France
Cihqdc Hzbmtiezeou Ubgnmkeapwget De Dvyvt Dijon France
Azhtrfsefn Pkqxmoyl Hupohoms Dp Mjbcuwfqr Marseille France
Ctufvl Hprctpxsudg Rxtxxogw Uaixxeshjzxkh Db Ttmrm Tours France
Cotc Dm Njpor Vandoeuvre Les Nancy France
Ctuygf Hsaborelgot Uuxedrltpwngo Rxbiu Reims France
Ifaethzg do Cahgzgwujeij Hnylrpjomxu Udfouykasoqte dk Szhvp Emwmdce (lwwdsdg Saint Priest En Jarez France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Not recruiting
01.01.2024

Trial locations

Investigated drugs:

Tocilizumab is a medication used in this clinical trial. It is designed to help reduce inflammation in the body. In this study, the researchers are looking at how stopping the use of tocilizumab affects people with a condition called Giant Cell Arteritis, which causes inflammation of the blood vessels. The trial is comparing two different ways of stopping the medication: one where it is stopped immediately and another where it is gradually reduced over a period of time. The goal is to see which method is better at preventing the condition from coming back.

Investigated diseases:

Giant Cell Arteritis – Giant Cell Arteritis is an inflammatory disease affecting the large and medium-sized arteries, primarily in the head. It often causes headaches, scalp tenderness, jaw pain, and vision problems. The inflammation can lead to narrowing or blockage of the affected arteries, reducing blood flow. Over time, this can result in complications such as vision loss or stroke if not managed. The disease is more common in older adults, particularly those over 50 years of age. It progresses with episodes of active inflammation and periods of remission.

Trial ID:
2023-505515-21-00
Protocol code:
MAGICA
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Venetoclax plus drug combination versus drug combination alone in children with relapsed acute myeloid leukemia

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +8

  • A study to evaluate the efficacy and safety of depemokimab and salbutamol sulfate in patients with chronic obstructive pulmonary disease and type 2 inflammation.

    Recruiting

    3 1 1
    Investigated drugs:
    Belgium Bulgaria Denmark France Germany Greece +6